Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee.
Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, Du J, Einsele H, Fernandez de Larrea C, Hajek R, Ho PJ, Kastritis E, Martinez-Lopez J, Mateos MV, Mikhael J, Moreau P, Nagarajan C, Nooka A, O'Dwyer M, Schjesvold F, Sidana S, van de Donk NW, Weisel K, Zweegman S, Raje N, Otero PR, Anderson LD Jr, Kumar S, Martin T; International Myeloma Working Group. Lin Y, et al. Among authors: o dwyer m. Lancet Oncol. 2024 Aug;25(8):e374-e387. doi: 10.1016/S1470-2045(24)00094-9. Epub 2024 May 28. Lancet Oncol. 2024. PMID: 38821074 Review.
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahlis N, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Mace JR, Raje N, Attal M, Tiab M, Macro M, Frenzel L, Leleu X, Ahmadi T, Chiu C, Wang J, Van Rampelbergh R, Uhlar CM, Kobos R, Qi M, Usmani SZ; MAIA Trial Investigators. Facon T, et al. N Engl J Med. 2019 May 30;380(22):2104-2115. doi: 10.1056/NEJMoa1817249. N Engl J Med. 2019. PMID: 31141632 Free PMC article. Clinical Trial.
Adoptive Immunotherapy and High-Risk Myeloma.
Duane C, O'Dwyer M, Glavey S. Duane C, et al. Cancers (Basel). 2023 May 6;15(9):2633. doi: 10.3390/cancers15092633. Cancers (Basel). 2023. PMID: 37174099 Free PMC article. Review.
Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.
Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A, Smith E, Briercheck E, Romee R, Alici E, Vivier E, O'Dwyer M, van de Velde H. Bisht K, et al. Among authors: o dwyer m. Exp Hematol Oncol. 2024 Nov 13;13(1):114. doi: 10.1186/s40164-024-00578-4. Exp Hematol Oncol. 2024. PMID: 39538354 Free PMC article. Review.
Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma.
Flanagan L, Coughlan A, Cosgrove N, Roe A, Wang Y, Gilmore S, Drozdz I, Comerford C, Ryan J, Minihane E, Parvin S, O'Dwyer M, Quinn J, Murphy P, Furney S, Glavey S, Chonghaile TN, Foundation LR, Ireland SF, Research BC. Flanagan L, et al. Among authors: o dwyer m. Haematologica. 2024 Sep 1;109(9):2930-2943. doi: 10.3324/haematol.2023.283771. Haematologica. 2024. PMID: 38511268 Free PMC article.
302 results